Diabetes mellitus, hypertension and medial temporal lobe atrophy: The LADIS study

Diabetic Medicine

Volumn 24, Issue 2, 2007, Pages 166-171

  Korf, E S C ^a,b   Van Straaten, E C W ^a,b,c   De Leeuw, F E ^b   Van Der Flier, W M ^a,b   Barkhof, F ^a,b   Pantoni, L ^d   Basile, A M ^d   Inzitari, D ^d   Erkinjuntti, T ^e   Wahlund, L O ^f   Rostrup, E ^g   Schmidt, R ^h   Fazekas, F ^h   Scheltens, P ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF HELSINKI   (Finland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Mental Health Services CPH   (Denmark)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Diabetes mellitus; Hypertension; Medial temporal lobe atrophy; Non disabled; White matter hyperintensities

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; NITRATE;

AGED; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TEMPORAL LOBE; WHITE MATTER;

AGED; AGED, 80 AND OVER; ATROPHY; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; RISK FACTORS; TEMPORAL LOBE;

EID: 33846648054     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02049.x     Document Type: Article

References (43)

1. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. Clinicopathologic correlates in Alzheimer's disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 1993; 7: 152-164.
2. Van Hoesen GW, Hyman BT. Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. Prog Brain Res 1990; 83: 445-457.
3. Den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005; 64: 263-267.
4. Korf ESC, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 2004; 44: 29-34.
5. Den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604-1610.
6. De Leeuw FE, Barkhof F, Scheltens Ph. White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology 2004; 62: 310-312.
7. De Leeuw FE, Korf ESC, Barkhof F, Scheltens Ph. Presence and progression of cerebral white matter lesions are risk factors for progression of medial temporal lobe atrophy in Alzheimer's diease. Stroke 2006; 37: 2248-2252.
8. Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H et al. Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology 2005; 24: 51-62.
9. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
10. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5T in Alzheimer's dementia and normal aging. AJNR Am J Neuroradiol 1987; 8: 421-426.
11. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
12. McLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull 1991; 109: 163-203.
13. Reitan RM. Validity of the Trail-Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271-276.
14. Ferris SH. General measures of cognition. Int Psychogeriatr 2003; 15: 215-217.
15. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG et al. A Short Physical Performance Battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M85-94.
16. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332: 556-561.
17. Guttmann CR, Benson R, Warfield SK, Wei X, Anderson MC, Hall CB et al. White matter abnormalities in mobility-impaired older persons. Neurology 2000; 54: 1277-1283.
18. The Euro-Qol Group. Euro-Qol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
19. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull 1988; 24: 709-711.
20. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271-284.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV). Washington DC: American Psychiatric Association, 1994.
22. World Health Organization. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-185.
23. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
24. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P et al. Atrophy of the medial temporal lobes on MRI in probable Alzheimer's disease and normal aging: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972.
25. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L et al. A 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
26. Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25-30 years and cognitive performance in older adults. Stroke 1998; 29: 2334-2340.
27. Korf ESC, Scheltens P, Barkhof F, de Leeuw F-E. Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer's disease? Dement Geriatr Cogn Disord 2005; 20: 331-337.
28. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000; 21: 57-62.
29. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC 3rd. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162-169.
30. DeCarli C, Scheltens P. Structural brain imaging. In: Erkinjuntti T, Gauthier S, eds. Vascular Factors in Dementia. London: Dunitz, 2002: 433-452.
31. Gadian DG, Aicardi J, Watkins KE, Porter DA, Mishkin M, Vargha-Khadem F. Developmental amnesia associated with early hypoxic-ischaemic injury. Brain 2000; 123: 499-507.
32. Smith MLRN, Siesjo BK. The density and distribution of ischemic brain injury in the rat following 2-10 min of forebrain ischemia. Acta Neuropathol (Berl) 1984; 64: 319-332.
33. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-19553.
34. Edbauer D, Willem M, Lammich S, Steiner H, Haass C. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J Biol Chem 2002; 277: 13389-13393.
35. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-32738.
36. Dickson DW, Sinicropi S, Yen SH, Ko LW, Mattiace LA, Bucala R et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 1996; 17: 733-743.
37. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKDPS 38. Br Med J 1998; 317: 703-713.
38. Schmidt R, Launer LJ, Nilsson LG, Pajak A, Sans S, Berger K et al. for the CASCADE Consortium. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004; 53: 687-692.
39. Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 2004; 33: 355-361.
40. Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H et al. NIDDM and blood pressure as risk factors for poor cognitive performance: the Framingham study. Diabetes Care 1997; 20: 1388-1395.
41. Jeerakathil T, Wolf PA, Beiser A, Hald JK, Au R, Kase CS et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004; 35: 1857-1861.
42. Dufouil C, de Kersaint-Gilly A, Besancon V, Levy C, Auffray E, Brunnereau L et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology 2001; 56: 921-926.
43. van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M et al. for the CASCADE Consortium. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44: 625-630.